Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma

Journal of Urology

Volumn 162, Issue 4, 1999, Pages 1519-1526

  Luo, Yi ^a   Chen, Xiaohong ^a   Han, Ruifa ^a   Chorev, Michael ^a   Dewolf, William C ^a   O'Donnell, Michael A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Immunotherapy; Mutation; Peptide; Ras p21

Indexed keywords

PROTEIN P21; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 0032819982     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68351-6     Document Type: Article

References (40)

1. Parada, L. F., Tabin, C. J., Shih, C. and Weinberg, R. A.: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature, 297: 474, 1982.
2. Vageli, D., Kiaris, H., Delakas, D., Anezinis, P., Cranidis, A. and Spandidos, D. A.: Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett., 107: 241, 1996.
3. Fontana, D., Bellina, M., Scoffone, C., Cagnazzi, E., Cappia, S., Cavallo, F., Russo, R. and Leonardo, E.: Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur. Urol., 29: 470, 1996.
4. Meyers, F. J., Gumerlock, P. H., Kokoris, S. P., deVere White, R. W. and McCormick, F.: Human bladder and colon carcinomas contain activated ras p21. Specific detection of twelfth codon mutants. Cancer, 63: 2177, 1989.
5. Abrams, S. I., Hand, P. H., Tsang, K. Y. and Schlom, J.: Mutant ras epitopes as targets for cancer vaccines. Semin. Oncol., 23: 118, 1996.
6. Bos, J. L.: ras oncogenes in human cancer: a review. Cancer Res., 49: 4682, 1989.
7. Lowy, D. R.: Function and regulation of ras. Annu. Rev. Biochem., 62: 851, 1993.
8. Rothbard, J. B. and Gefter, M. L.: Interactions between immunogenic peptides and MHC proteins. Annu. Rev. Immunol., 9: 527, 1991.
9. Peace, D. J., Chen, W., Nelson, H. and Cheever, M. A.: T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol., 146: 2059, 1991.
10. + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur. J. Immunol., 25: 2588, 1995.
11. Peace, D. J., Smith, J. W., Chen, W., You, S-G., Cosand, W. L., Blake, J. and Cheever, M. A.: Lysis of Ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptide. J. Exp. Med., 179: 473, 1994.
12. + T cell responses. Eur. J. Immunol., 26: 435, 1996.
13. Jung, S. and Schluesener, H. J.: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med., 173: 273, 1991.
14. Gedde-Dahl, III, T., Eriksen, J. A., Thorsby, E. and Gaudernak, G.: T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 Ras-derived synthetic peptides. Hum. Immunol., 33: 266, 1992.
15. Fossum, B., Gedde-Dahl, III, T., Hansen, T., Eriksen, J. A., Thorsby, E. and Gaudernack, G.: Overlapping epitopes encompassing a point mutation (12 Gly > Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur. J. Immunol., 23: 2687, 1993.
16. Tsang, K. Y., Nieroda, C. A. and DeFilippi, R.: Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res., 3: 183, 1994.
17. Van Elsas, A., Nijman, H. W., Van der Minne, C. E., Mourer, J. S., Kast, W. M., Melief, C. J. M. and Schrier, P. I.: Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 Ras peptide presented by HLA-A*0201. Int. J. Cancer, 61: 389, 1995.
18. O'Donnell, M. A., Aldovini, A., Duda, R. B., Yang, H., Szilvasi, A., Young, R. A. and DeWolf, W. C.: Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect. Immun., 62: 2508, 1994.
19. Luo, Y., Szilvasi, A., Chen, X., DeWolf, W. C. and O'Donnell, M. A.: A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin. Diag. Lab. Immunol., 3: 761, 1996.
20. Fujimoto, T., O'Donnell, M. A., Szilvasi, A., Yang, H. and Duda, R. B.: Bacillus Calmette-Guerin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol. Immunother., 42: 280, 1996.
21. d. Science, 256: 1817, 1992.
22. Ozdemirli, M., el-Khatib, M., Bastiani, L., Akdeniz, H., Kuchroo, V. and Ju, S. T.: The cytotoxic process of CD4 Th1 clones. J. Immunol., 149: 1889, 1992.
23. Parronchi, P., De Carli, M., Manetti, R., Simonelli, C., Sampognaro, S., Piccinni, M. P., Macchia, D., Maggi, E., Del Prete, G. and Romagnani, S.: IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol., 149: 2977, 1992.
24. + T cell clones correlates with IFN-gamma production in mouse strains having a BALB/c background. J. Immunol., 150: 3793, 1993.
25. Klein, G. and Boon, T.: Tumor immunology: present perspectives. Curr. Opin. Immunol., 5: 687, 1993.
26. Roth, C., Rochlitz, C. and Kourilsky, P.: Immune response against tumors. Adv. Immunol., 57: 281, 1994.
27. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Herrmann, S. H. and Ritz, J.: Response of human natural killer (NK) cells to NKSF: Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med., 175: 779, 1992.
28. Gately, M. K., Wolitzky, A. G., Quinn, P. M. and Chizzonite, R.: Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol., 143: 127, 1992.
29. Trinchieri, G.: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13: 251, 1995.
30. Farrar, M. A. and Schreiber, R. D.: The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol., 11: 571, 1993.
31. Noguchi, Y., Richards, E. C., Chen, Y-T. and Old, L. J.: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci., 92: 2219, 1995.
32. Wigley, C. B. and Summerhayes, I. C.: Loss of LETS protein is not a marker for salivary gland or bladder epithelial cell transformation. Exp. Cell. Res., 118: 394, 1979.
33. Ross, R. K., Jones, P. A. and Yu, M. C.: Bladder cancer epidemiology and pathogenesis. Semin. Oncol., 23: 536, 1996.
34. Levesque, P., Ramchurren, N., Saini, K., Joyce, A., Libertino, J. and Summerhayes, I. C.: Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int. J. Cancer, 55: 785, 1993.
35. Fitzgerald, J. M., Ramchurren, N., Rieger, K., Levesque, P., Silverman, M., Libertino, J. A. and Summerhayes, I. C.: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J. Natl. Cancer Inst., 87: 129, 1995.
36. Saito, S., Hata, M., Fukuyama, R., Sakai, K., Kudoh, J., Tazaki, H. and Shimizu, N.: Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int. J. Urol., 4: 178, 1997.
37. Czerniak, B., Cohen, G. L., Etkind, P., Deitch, D., Simmons, H., Herz, F. and Koss, L. G.: Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum. Pathol., 23: 1199, 1992.
38. Burchill, S. A., Neal, D. E. and Lunec, J.: Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br. J. Urol., 73: 516, 1994.
39. O'Donnell, M. A. and DeWolf, W. C.: Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg. Oncol. Clin. N. Am., 4: 189, 1995.
40. O'Donnell, M. A.: The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotech., 15: 512, 1997.